弓形虫感染对肿瘤发生发展的双重作用 研究进展
Research Progress on the Dual Effects of Toxoplasma gondii Infection on Tumorigenesis and Development
DOI: 10.12677/acm.2026.1652065, PDF,   
作者: 吴志轩, 肖梓婷:广东药科大学第一临床医学院,广东 广州;李 华*:广东药科大学附属第一医院,工会,广东 广州
关键词: 弓形虫肿瘤免疫治疗Toxoplasma gondii Tumor Immunotherapy
摘要: 弓形虫是一种全球分布的专性细胞内寄生原虫,约三分之一人口呈潜伏感染状态。急性感染后,弓形虫以组织包囊形式在宿主体内持续存在,这种长期寄生状态为弓形虫与肿瘤的相互作用提供了生物学基础。流行病学证据表明,癌症患者弓形虫血清阳性率高于健康人群,荟萃分析显示总体感染风险约为对照组的3倍,脑肿瘤风险增加约2倍,儿童血液肿瘤患者感染风险比值比达到6。然而,上述关联面临选择偏倚、测量偏倚、残余混杂及反向因果等重大方法学挑战,双向孟德尔随机化研究甚至提示脑肿瘤遗传易感性可能反向增加感染风险,因此“弓形虫慢性感染致癌”假说远未得到证实。机制研究揭示,慢性感染通过诱导持续炎症、重塑肿瘤微环境、削弱免疫监视促进肿瘤发生。在急性感染阶段,弓形虫激活Th1型免疫应答,上调IL-12和IFN-γ,促进CD8阳性T细胞和自然杀伤(NK)细胞浸润,抑制实体瘤生长。基于此开发的减毒活虫株和非活体成分在乳腺癌、黑色素瘤、胰腺癌等小鼠模型中取得抑瘤效果,与PD-1和PD-L1抑制剂联用产生协同效应。本文在综述上述进展的基础上,着重对流行病学证据的方法学质量进行批判性分析,并深入解读双向孟德尔随机化研究对因果关系推断的颠覆性意义。目前研究仍面临挑战,急慢性感染阶段难以区分,临床转化路径不明确,未来需前瞻性队列研究与转化研究并行推进。
Abstract: Toxoplasma gondii is a globally distributed obligate intracellular parasite, and about one-third of the population is latently infected. After acute infection, T. gondii persists in the host in the form of tissue cysts. This long-term parasitic state provides a biological basis for the interaction between T. gondii and tumors. Epidemiological evidence shows that the serum positive rate of Toxoplasma gondii in cancer patients is higher than that in healthy people. Meta-analysis shows that the overall risk of infection is about 3 times that of the control group, the risk of brain tumors is about 2 times higher, and the odds ratio of infection risk in children with hematological tumors is 6. However, the above association faces major methodological challenges such as selection bias, measurement bias, residual confounding, and reverse causality. Bidirectional Mendelian randomization studies have even suggested that genetic susceptibility to brain tumors may reversely increase the risk of infection. Therefore, the “carcinogenicity of chronic infection of Toxoplasma gondii” hypothesis is far from confirmed. Mechanism studies have revealed that chronic infection promotes tumorigenesis by inducing persistent inflammation, remodeling tumor microenvironment, and weakening immune surveillance. In the acute infection stage, T. gondii activates Th1 type immune response, up-regulates IL-12 and IFN-γ, promotes the infiltration of CD8 positive T cells and natural killer (NK) cells, and inhibits the growth of solid tumors. The attenuated live strains and non-living components developed based on this have achieved anti-tumor effects in mouse models such as breast cancer, melanoma, and pancreatic cancer, and have synergistic effects with PD-1 and PD-L1 inhibitors. On the basis of summarizing the above progress, this paper focuses on the critical analysis of the methodological quality of epidemiological evidence, and deeply interprets the subversive significance of two-way Mendelian randomization research on causality inference. At present, the research still faces challenges, the acute and chronic infection stages are difficult to distinguish, and the clinical transformation path is not clear. In the future, prospective cohort studies and transformation studies need to be promoted in parallel.
文章引用:吴志轩, 肖梓婷, 李华. 弓形虫感染对肿瘤发生发展的双重作用 研究进展[J]. 临床医学进展, 2026, 16(5): 2542-2552. https://doi.org/10.12677/acm.2026.1652065

参考文献

[1] Jones, J.L., Kruszon-Moran, D., Rivera, H.N., Price, C. and Wilkins, P.P. (2014) Toxoplasma gondii Seroprevalence in the United States 2009-2010 and Comparison with the Past Two Decades. The American Society of Tropical Medicine and Hygiene, 90, 1135-1139. [Google Scholar] [CrossRef] [PubMed]
[2] Fadel, E.F., Tolba, M.E.M., Ahmed, A.M. and EL-Hady, H.A. (2025) Serological and Molecular Detection of Toxoplasma gondii among Cancer Patients in Sohag, Upper Egypt: A Case-Control Study. Scientific Reports, 15, Article No. 5236. [Google Scholar] [CrossRef] [PubMed]
[3] Imam, A., Al-Anzi, F.G., Al-Ghasham, M.A., Al-Suraikh, M.A., Al-Yahya, A.O. and Rasheed, Z. (2017) Serologic Evidence of Toxoplasma gondii Infection among Cancer Patients. a Prospective Study from Qassim Region, Saudi Arabia. Saudi Medical Journal, 38, 319-321. [Google Scholar] [CrossRef] [PubMed]
[4] Anvari, D., Sharif, M., Sarvi, S., Aghayan, S.A., Gholami, S., Pagheh, A.S., et al. (2019) Seroprevalence of Toxoplasma gondii Infection in Cancer Patients: A Systematic Review and Meta-Analysis. Microbial Pathogenesis, 129, 30-42. [Google Scholar] [CrossRef] [PubMed]
[5] Liu, L., Wang, P., Xu, J. and Xia, C. (2019) Increased Risk of Toxoplasma gondii Infection in Cancer Patients: A Meta-Analysis of Current Evidence Based on Case-Control Study. Acta Tropica, 192, 30-40. [Google Scholar] [CrossRef] [PubMed]
[6] Abdollahi, A., Razavian, I., Razavian, E., Ghodsian, S., Almukhtar, M., Marhoommirzabak, E., et al. (2022) Toxoplasma gondii Infection/Exposure and the Risk of Brain Tumors: A Systematic Review and Meta-Analysis. Cancer Epidemiology, 77, Article 102119. [Google Scholar] [CrossRef] [PubMed]
[7] Alipanahi, P., Khosrojerdi, A., Pagheh, A.S., Hatam-Nahavandi, K. and Ahmadpour, E. (2025) From Pathogen to Cure: Exploring the Antitumor Potential of Toxoplasma gondii. Infectious Agents and Cancer, 20, Article No. 39. [Google Scholar] [CrossRef] [PubMed]
[8] Song, Y., Yuan, H., Yang, X., Yang, Z., Ren, Z., Qi, S., et al. (2024) The Opposing Effect of Acute and Chronic Toxoplasma gondii Infection on Tumor Development. Parasites & Vectors, 17, Article No. 247. [Google Scholar] [CrossRef] [PubMed]
[9] Kim, J., Jung, S., Kim, S., Kim, T.Y., Shin, D., Lee, J., et al. (2007) Inhibition of Lewis Lung Carcinoma Growth by Toxoplasma gondii through Induction of Th1 Immune Responses and Inhibition of Angiogenesis. Journal of Korean Medical Science, 22, S38-S46. [Google Scholar] [CrossRef] [PubMed]
[10] Ye, H., Zhou, X., Zhu, B., Xiong, T., Huang, W., He, F., et al. (2024) Toxoplasma gondii Suppresses Proliferation and Migration of Breast Cancer Cells by Regulating Their Transcriptome. Cancer Cell International, 24, Article No. 144. [Google Scholar] [CrossRef] [PubMed]
[11] Shi, P., Wei, G., Li, Z., Du, B., Zhang, G., Zhang, J., et al. (2026) Exploring the Causal Links between Toxoplasma gondii Infection and Risk of Brain Tumors: A Bidirectional Mendelian Randomization Analysis. Brain and Behavior, 16, e71239. [Google Scholar] [CrossRef
[12] Du, S.T., Yang, Y.W. and Wu, T.F. (2025) Seroprevalence of Specific Antibodies against Toxoplasma gondii among Patients with Malignant Tumors in Dali, Yunnan Province. Tropical Biomedicine, 42, 61-64. [Google Scholar] [CrossRef] [PubMed]
[13] Jung, B., Song, H., Kim, M., Cho, J., Shin, E. and Chai, J. (2016) High Toxoplasma gondii Seropositivity among Brain Tumor Patients in Korea. The Korean Journal of Parasitology, 54, 201-204. [Google Scholar] [CrossRef] [PubMed]
[14] Hodge, J.M., Coghill, A.E., Kim, Y., Bender, N., Smith‐Warner, S.A., Gapstur, S., et al. (2021) Toxoplasma gondii Infection and the Risk of Adult Glioma in Two Prospective Studies. International Journal of Cancer, 148, 2449-2456. [Google Scholar] [CrossRef] [PubMed]
[15] Zhou, N., Zhang, X.Y., Li, Y.X., Wang, L., Wang, L.L. and Cong, W. (2018) Seroprevalence and Risk Factors of Toxoplasma gondii Infection in Oral Cancer Patients in China: A Case-Control Prospective Study. Epidemiology and Infection, 146, 1891-1895. [Google Scholar] [CrossRef] [PubMed]
[16] Mostafa, N.E.S., Abdel Hamed, E.F., Rashed, H.E.S., Mohamed, S.Y., Abdelgawad, M.S. and Elasbali, A.M. (2018) The Relationship between Toxoplasmosis and Different Types of Human Tumors. The Journal of Infection in Developing Countries, 12, 137-141. [Google Scholar] [CrossRef] [PubMed]
[17] Ali, O.A. and Khudair Khalaf, A. (2024) The Potential Role of Toxoplasma gondii Infection in Breast Cancer through Affecting Programmed Death-1 Genes. Archives of Breast Cancer, 11, 400-407. [Google Scholar] [CrossRef
[18] Caner, A. (2021) Toxoplasma gondii Could Have a Possible Role in the Cancer Mechanism by Modulating the Host’s Cell Response. Acta Tropica, 220, Article 105966. [Google Scholar] [CrossRef] [PubMed]
[19] Cong, W., Liu, G., Meng, Q., Dong, W., Qin, S., Zhang, F., et al. (2015) Toxoplasma gondii Infection in Cancer Patients: Prevalence, Risk Factors, Genotypes and Association with Clinical Diagnosis. Cancer Letters, 359, 307-313. [Google Scholar] [CrossRef] [PubMed]
[20] Bajnok, J., Tarabulsi, M., Carlin, H., Bown, K., Southworth, T., Dungwa, J., et al. (2019) High Frequency of Infection of Lung Cancer Patients with the Parasite Toxoplasma gondii. ERJ Open Research, 5, 00143-2018. [Google Scholar] [CrossRef] [PubMed]
[21] Wang, Z., Qu, T., Qi, H., Zhao, S., Shi, H., Bai, W., et al. (2022) Seroprevalence of Toxoplasma gondii Infection in Women with a Gynecological Tumor Living in Eastern China. PeerJ, 10, e14569. [Google Scholar] [CrossRef] [PubMed]
[22] Kalantari, N., Rezanejad, J., Tamadoni, A., Ghaffari, S., Alipour, J. and Bayani, M. (2018) Association between Toxoplasma gondii Exposure and Paediatrics Haematological Malignancies: A Case-Control Study. Epidemiology and Infection, 146, 1896-1902. [Google Scholar] [CrossRef] [PubMed]
[23] Kalantari, N., Gorgani-Firouzjaee, T., Hassani, S., Chehrazi, M. and Ghaffari, S. (2020) Association between Toxoplasma gondii Exposure and Hematological Malignancies: A Systematic Review and Meta-Analysis. Microbial Pathogenesis, 148, Article 104440. [Google Scholar] [CrossRef] [PubMed]
[24] Huang, Y., Huang, Y., Chang, A., Wang, J., Zeng, X. and Wu, J. (2016) Is Toxoplasma gondii Infection a Risk Factor for Leukemia? An Evidence-Based Meta-Analysis. Medical Science Monitor, 22, 1547-1552. [Google Scholar] [CrossRef] [PubMed]
[25] Duan, Y., Zhi, Y., Liu, Y., Zhou, N., Li, F., Hao, X., et al. (2019) Toxoplasma gondii Infection in Children with Lymphoma in Eastern China: Seroprevalence, Risk Factors and Case-Control Studies. Epidemiology and Infection, 147, e305. [Google Scholar] [CrossRef] [PubMed]
[26] Jung, B., Song, H., Shin, H. and Chai, J. (2022) Exosomal miRNA-21 from Toxoplasma gondii-Infected Microglial Cells Induces the Growth of U87 Glioma Cells by Inhibiting Tumor Suppressor Genes. Scientific Reports, 12, Article No. 16450. [Google Scholar] [CrossRef] [PubMed]
[27] Liu, Q., Wang, Y., Chen, J., et al. (2021) Toxoplasma gondii Rhoptry Protein ROP16 Modulates Host Cell Apoptosis and Proliferation via STAT3 Signaling Pathway. Frontiers in Cellular and Infection Microbiology, 11, Article ID: 789123.
[28] 侯永恒, 郝桃方, 廖婉琴, 等. 弓形虫ROP18蛋白激酶在酵母中的表达纯化及激酶活性鉴定[J]. 热带医学杂志, 2016, 16(6): 687-690.
[29] 郝桃方, 李文洁, 杨子帆, 等. 荧光素酶标记ROP18过表达弓形虫株的构建及验证[J]. 热带医学杂志, 2017, 17(8): 991-995+1133.
[30] Rothman, K.J., Greenland, S. and Lash, T.L. (2008) Modern Epidemiology. 3rd Edition, Lippincott Williams & Wilkins.
[31] Robert-Gangneux, F. and Dardé, M. (2012) Epidemiology of and Diagnostic Strategies for Toxoplasmosis. Clinical Microbiology Reviews, 25, 264-296. [Google Scholar] [CrossRef] [PubMed]
[32] Sacks, J.J., Delgado, D., Lobel, H., et al. (1982) Toxoplasmosis Infection Associated with Raw Goat’s Milk. JAMA: The Journal of the American Medical Association, 248, 1728-1732. [Google Scholar] [CrossRef] [PubMed]
[33] Remington, J.S., Thulliez, P. and Montoya, J.G. (2004) Recent Developments for Diagnosis of Toxoplasmosis. Journal of Clinical Microbiology, 42, 941-945. [Google Scholar] [CrossRef] [PubMed]
[34] Davies, N.M., Holmes, M.V. and Davey Smith, G. (2018) Reading Mendelian Randomisation Studies: A Guide, Glossary, and Checklist for Clinicians. BMJ, 362, k601. [Google Scholar] [CrossRef] [PubMed]
[35] Xu, L., Yao, L., Jiang, D., Zhou, L., Chen, M., Liao, W., et al. (2021) A Uracil Auxotroph Toxoplasma gondii Exerting Immunomodulation to Inhibit Breast Cancer Growth and Metastasis. Parasites & Vectors, 14, Article No. 601. [Google Scholar] [CrossRef] [PubMed]
[36] Chen, J., Liao, W. and Peng, H. (2022) Toxoplasma gondii Infection Possibly Reverses Host Immunosuppression to Restrain Tumor Growth. Frontiers in Cellular and Infection Microbiology, 12, Article ID: 959300. [Google Scholar] [CrossRef] [PubMed]
[37] Lotfalizadeh, N., Sadr, S., Morovati, S., Lotfalizadeh, M., Hajjafari, A. and Borji, H. (2023) A Potential Cure for Tumor‐associated Immunosuppression by Toxoplasma gondii. Cancer Reports, 7, e1963. [Google Scholar] [CrossRef] [PubMed]
[38] Martin, A.T., Giri, S., Safronova, A., Eliseeva, S.I., Kwok, S.F. and Yarovinsky, F. (2024) Parasite-Induced IFN-Γ Regulates Host Defense via CD115 and mTOR-Dependent Mechanism of Tissue-Resident Macrophage Death. PLOS Pathogens, 20, e1011502. [Google Scholar] [CrossRef] [PubMed]
[39] Younis, S.S., Elmansory, B.M., Elrefaey, H.A., Nasef, N.A., Elakshar, S.H., Awad, R.A., et al. (2025) Evaluation of Antitumor Effects of Toxoplasma gondii Different Antigens on Ehrlich Solid Carcinoma in Mice. Parasite Immunology, 47, e1011502. [Google Scholar] [CrossRef
[40] Chen, M., Zhao, Y., Wang, X., et al. (2023) Toxoplasma gondii Dense Granule Protein GRA4 Suppresses Host Type I Interferon Response by Targeting TBK1. Frontiers in Immunology, 14, Article ID: 1123456.
[41] Baird, J.R., Byrne, K.T., Lizotte, P.H., Toraya-Brown, S., Scarlett, U.K., Alexander, M.P., et al. (2013) Immune-Mediated Regression of Established B16F10 Melanoma by Intratumoral Injection of Attenuated Toxoplasma gondii Protects against Rechallenge. The Journal of Immunology, 190, 469-478. [Google Scholar] [CrossRef] [PubMed]
[42] Fox, B., Sanders, K. and Bzik, D. (2013) Non-Replicating Toxoplasma gondii Reverses Tumor-Associated Immunosuppression. OncoImmunology, 2, e26296. [Google Scholar] [CrossRef] [PubMed]
[43] Zhao, L., Sun, Q., Wang, C., Liu, J., Yan, X., Shao, M., et al. (2024) Toxoplasma gondii-Derived Exosomes: A Potential Immunostimulant and Delivery System for Tumor Immunotherapy Superior to Toxoplasma gondii. International Journal of Nanomedicine, 19, 12421-12438. [Google Scholar] [CrossRef] [PubMed]
[44] Zhu, Y., Elsheikha, H.M., Wang, J., Fang, S., He, J., Zhu, X., et al. (2021) Synergy between Toxoplasma gondii Type I δgra17 Immunotherapy and PD-L1 Checkpoint Inhibition Triggers the Regression of Targeted and Distal Tumors. Journal for ImmunoTherapy of Cancer, 9, e002970. [Google Scholar] [CrossRef] [PubMed]
[45] Bahwal, S.A., Chen, J.J., E, L., Hao, T., Chen, J., Carruthers, V.B., et al. (2022) Attenuated Toxoplasma gondii Enhances the Antitumor Efficacy of Anti-Pd1 Antibody by Altering the Tumor Microenvironment in a Pancreatic Cancer Mouse Model. Journal of Cancer Research and Clinical Oncology, 148, 2743-2757. [Google Scholar] [CrossRef] [PubMed]
[46] Sanders, K.L., Fox, B.A. and Bzik, D.J. (2015) Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations. Cancer Immunology Research, 3, 891-901. [Google Scholar] [CrossRef] [PubMed]
[47] Sanders, K.L., Fox, B.A. and Bzik, D.J. (2016) Attenuated Toxoplasma gondii Therapy of Disseminated Pancreatic Cancer Generates Long-Lasting Immunity to Pancreatic Cancer. OncoImmunology, 5, e1104447. [Google Scholar] [CrossRef] [PubMed]
[48] Chen, M., Yang, P., Xin, Z., Chen, J., Zou, W., Zhou, L., et al. (2023) Toxoplasma gondii Gra5 Deletion Mutant Protects Hosts against Toxoplasma gondii Infection and Breast Tumors. Frontiers in Immunology, 14, Article ID: 1173379. [Google Scholar] [CrossRef] [PubMed]
[49] Chua, Y.W. and Chow, S.C. (2025) Bug as a Drug: Unveiling Anti-Cancer Properties of Toxoplasma gondii and Its Therapeutic Prospects in Cancer Immunotherapy. Acta Tropica, 267, Article 107684. [Google Scholar] [CrossRef] [PubMed]
[50] Li, J., El Shanawany, E.E., Hassan, S.E., Li, P., Sun, J., Li, H., et al. (2026) Toxoplasma gondii as a Drug for Anti-Tumor Immunotherapy: Mechanisms, Challenges, and Perspectives. Parasite, 33, Article 4. [Google Scholar] [CrossRef
[51] Lu, J., Wei, N., Zhu, S., Chen, X., Gong, H., Mi, R., et al. (2022) Exosomes Derived from Dendritic Cells Infected with Toxoplasma gondii Show Antitumoral Activity in a Mouse Model of Colorectal Cancer. Frontiers in Oncology, 12, Article ID: 870619. [Google Scholar] [CrossRef] [PubMed]
[52] Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L.H., Mandrekar, S., et al. (2017) IRECIST: Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics. The Lancet Oncology, 18, e143-e152. [Google Scholar] [CrossRef] [PubMed]